CATALYST PHARMACEUTICALS, INC. (NASDAQ:CPRX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item5.02(e)
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers |
At the Companys 2017 Annual Meeting of Stockholders held on
May25, 2017, Patrick J. McEnany, Philip H. Coelho, Charles B.
OKeeffe, David S. Tierney, Richard J. Daly and Donald A. Denkhaus
were elected to the Companys Board of Directors to serve until
the 2018 Annual Meeting of Stockholders or until their successor
is duly elected and qualified, or until their earlier death,
resignation or removal.
| Item5.07 |
Submission of Matters to a Vote of Security Holders |
On May25, 2017, the Company held its Annual Meeting of
Stockholders at the Hyatt Regency Coral Gables, 50 Alhambra
Plaza, Coral Gables, Florida. The final voting results on the
matters considered at the meeting are as follows:
| 1. | Election of Directors: |
|
Name |
Votes For | VotesWithheld | BrokerNon-Votes | |||||||||
|
Patrick J. McEnany |
32,138,470 | 373,092 | 36,638,614 | |||||||||
|
Philip H. Coelho |
32,123,604 | 387,958 | 36,638,614 | |||||||||
|
Charles B. OKeeffe |
32,133,665 | 377,897 | 36,638,614 | |||||||||
|
David S. Tierney |
32,128,018 | 383,544 | 36,638,614 | |||||||||
|
Richard J. Daly |
31,988,632 | 522,930 | 36,638,614 | |||||||||
|
Donald A. Denkhaus |
32,130,554 | 381,008 | 36,638,614 |
| 2. |
Approval of an amendment to the Companys 2014 Stock Incentive Plan increasing the shares available for issuance under the plan by 3million shares: |
|
Votes For |
Votes Against |
Votes Abstained |
Broker Non-Votes |
|||
|
29,667,830 |
2,278,579 | 565,153 | 36,638,614 |
| 3. | Approval of the Companys Stockholders Rights Plan: |
|
Votes For |
Votes Against |
Votes Abstained |
Broker Non-Votes |
|||
|
27,348,628 |
5,080,854 | 82,080 | 36,638,614 |
| 4. |
Ratification of the selection of Grant Thornton, LLP as the Companys independent registered public accounting firm for the fiscal year ending December31, 2017: |
|
Votes For |
Votes Against |
Votes Abstained |
||
|
68,432,581 |
241,998 | 475,597 |
2
| Item9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits |
| 10.1 |
Amendment No.2 to the Companys 2014 Stock Incentive Plan (incorporated by reference to Annex A to the Companys 2017 Annual Meeting Proxy Statement dated April14, 2017) |
|
| 10.2 |
Rights Agreement, dated September20, 2011, between the Company and Continental Stock Transfer and Trust Company, as amended by that certain Amendment No.1 to Rights Agreement, dated as of September19, 2016, between the Company and Continental Stock Transfer and Trust Company (incorporated by reference to Annex B to the Companys 2017 Annual Meeting Proxy Statement dated April14, 2017) |
3
About CATALYST PHARMACEUTICALS, INC. (NASDAQ:CPRX)
Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company’s Firdapse is indicated for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). Firdapse consists of the phosphate salt of amifampridine. The Company has completed the Phase III trial of Firdapse. The Company’s CPP-109 (vigabatrin) is a gamma-aminobutyric acid (GABA) aminotransferase inhibitor. CPP-109 is indicated for the treatment of Tourette’s Disorder. The Company’s CPP-115 is a GABA aminotransferase inhibitor. CPP-115 is indicated for the treatment of selected neurological indications, such as complex partial seizures and Tourette’s Disorder, and epilepsy. CATALYST PHARMACEUTICALS, INC. (NASDAQ:CPRX) Recent Trading Information
CATALYST PHARMACEUTICALS, INC. (NASDAQ:CPRX) closed its last trading session 00.00 at 2.17 with 241,681 shares trading hands.
